Haleon (HLN) Non-Current Deferred Tax Liability (2021 - 2025)
Haleon (HLN) posted Non-Current Deferred Tax Liability of $4.3 billion for Q4 2025, little changed on a QoQ basis from $4.3 billion in Q4 2024, and little changed year-over-year from $4.3 billion in Q4 2024.
Haleon (HLN) Non-Current Deferred Tax Liability (2021 - 2025) Analysis & Trends
Haleon's Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $4.3 billion for Q4 2025.
- Quarterly Non-Current Deferred Tax Liability changed 0.41% year-over-year to $4.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.3 billion (changed 0.41% YoY) and the FY2025 annual result came in at $4.2 billion, down 0.88% from the prior year.
- Non-Current Deferred Tax Liability was $4.3 billion for Q4 2025 at Haleon, roughly flat from $4.3 billion in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $4.5 billion in Q4 2021 and bottomed at -$4.6 billion in Q2 2022.
- A 5-year average of $1.1 billion and a median of $4.3 billion in 2025 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability retreated 6.66% — and 2023, when it climbed 6.5%.
- Haleon's Non-Current Deferred Tax Liability stood at $4.5 billion in 2021, then declined by 6.66% to $4.2 billion in 2022, then advanced by 2.47% to $4.3 billion in 2023, then slipped by 0.56% to $4.3 billion in 2024, then decreased by 0.41% to $4.3 billion in 2025.
- Business Quant data shows HLN's Non-Current Deferred Tax Liability at $4.3 billion in Q4 2025, $4.3 billion in Q4 2024, and -$4.2 billion in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.29 Bn |
| Dec 31, 2025 | 4.29 Bn |
| Dec 31, 2024 | 4.30 Bn |
| Dec 31, 2024 | 4.30 Bn |
| Jun 30, 2024 | -4.22 Bn |
| Jun 30, 2024 | -4.22 Bn |
| Dec 31, 2023 | 4.33 Bn |
| Dec 31, 2023 | 4.33 Bn |
| Jun 30, 2023 | -4.30 Bn |
| Jun 30, 2023 | -4.30 Bn |
| Dec 31, 2022 | 4.22 Bn |
| Dec 31, 2022 | 4.22 Bn |
| Jun 30, 2022 | -4.60 Bn |
| Jun 30, 2022 | -4.60 Bn |
| Dec 31, 2021 | 4.53 Bn |
| Dec 31, 2021 | 4.53 Bn |